INCIDENCE OF POLYMORPHISM OF *GSTT1* GENE IN BENIGN PROSTATIC HYPERPLASIA IN BASRA PROVINCE

Jihad Abdulameer Ahmed* ; **Asad Mohammed Kadhem****

* Pathology Dept., College of Veterinary medicine, Uni. of Basra, Iraq.

** Surgery Dept., College of Dentistry, Uni. of Basra, Iraq.

E.Mail: dr.jihad.vet@gmail.com

ABSTRACT

Prostate tumor has become a major public health problem concern worldwide for its high morbidity and mortality levels, therefore It is the second leading cause of cancer related to death in the world, on the other hand the prostate tumor is a multiphase process that depend on various risk factors included genetic factors which play an important role in it initiation and progression, so that the *GSTT1* gene polymorphisms might be involved in inactivation of procarcinogens that contribute to the genesis and2 progression of cancers. The methodology consist of DNA extraction from 40 patient of benign prostatic hyperplasia and 40 healthy served as controls, then done the amplification of GSTT1 gene to study the polymorphism of it. The results showed that 77.5% of patients of benign prostatic hyperplasia have polymorphism with *GSTT1* null genotype when compared with controls. We concluded that the polymorphism of *GSTT1* gene may considered as risk factor to initiate prostate tumor.

Key words: Benign prostatic hyperplasia, Polymorphism, GSTT1 gene.

INTRODUCTION

Prostate cancer is the most commonly diagnosed type of cancer among men and it remains the second leading cause of cancer deaths worldwide (Siegel *et al.,* 2012). Both genetic and environmental factors are considered to play important roles in the occurrence of

prostate cancer, moreover, the etiology of prostate cancer remains unresolved, although genetic polymorphisms may play important roles in the genesis of prostate cancer (Wang *et al.,* 2012). Therefore, prostate cancer is the most common cancer among men in industrialized countries with the main risk factor being the age of over 50. Prostate cancer is uncommon in men younger than 45, but becomes more common with increasing age. The average age at the time of diagnosis is 65 (Tewari, *et al.,* 2004 ; Jang, *et al.,* 2007).

Glutathione-S-transferases (GST) are phase II enzymes which are responsible for catalyzing the biotransformation of a variety of electrophilic compounds, and have therefore a central role in the detoxification of activated metabolites of procarcinogens produced by phase I reactions (Nebert and Vasiliou, 2004). The *GSTT1* member of the multigene

family are candidate cancer-predisposing genes. The relation of polymorphism in this gene to chemical carcinogenesis has been extensively studied in various populations. Several population-based studies have reported prevalence ranging from 13% to 25% for the *GSTT1*-null genotype among white Europeans (Rebbeck, 1997 ; Garte *et al.,* 2001).

GSTs are generally involved in detoxification, but they are also important in activating and inactivating oxidative metabolites of carcinogenic compounds associated with causing prostate cancer (Gibbs *et al.,* 1996). Combinations of various unfavorable deletion genotypes theoretically confer an even higher risk to patients with prostate cancer. An increased frequency of GST genotypes has been associated with several malignancies (Lee *et al.,* 1998 ; Sreelekha *et al.,* 2001). Some studies indicate that GST

polymorphisms are associated with prostate cancer (Gsur *et al.,* 2001 ; Nakazato *et al.,* 2003). Therefore, in the present study, we attempt to determined the genotypic frequency of the genotype *GSTT1* null polymorphism, to understand whether the GST polymorphisms are associated with the risk of benign prostatic hyperplasia in Basra province.

MATERIALS & METHODS

A total 40 patients of benign prostatic hyperplasia and equal number of healthy controls were studied from the periods between 15th January 2015 to 15th June 2015. The patients was confirmed diagnosis by clinical examination and histopathology which had a benign prostatic hyperplasia, then we take the history of smoking status, age and geographical location of the patients.

A 1.5 ml of blood was taken from the patients as well as controls and put in anticoagulant tube which immediately transferred to the central research unit in the college of Vet. Medicine / Uni. of Basra to extract the DNA from whole blood was performed by using Geneaid mini kit (Geneaid kit, USA), the steps of the method was according to the manufacturing company, and genes profile was carried out by electrophoresis according to Green and Sambrook, (2012). The genomic DNA was measured by using Nano drop spectrophotometer (Optizen / Korea) and the DNA purity measured depending on the sample absorbance at wavelengths 260nm. A ratio equal to 100µg/1µl considered a pure DNA according to (Ahmed, 2014).Then DNA stored at -20C° until genotype analysis.

A dultiplex polymerase chain reaction (dPCR) method was used to detect either the presence or absence of *GSTT1* gene in the

genomic DNA samples and *β-globin* gene was co-amplified and used as an internal control in the same PCR tubes (Chen *et al.,* 1996).

Genomic DNA (100 ng) was amplified in a total volume of 25 µl reaction mixture containing 25 pmol of each (*GSTT1* gene: forward 5'-TTC CTT ACT GGT CCT CAC ATC TC-3' and reverse 5'- TCA CCG GAT CAT GGC CAG CA-3', according to GenBank accession no. NM_000853) and 25 pmol *β-globin* gene primers (forward 5'-CAA CTT CAT CCA CGT TCA CC-3' and reverse 5'- GAA GAG CCA AGG ACA GGT AC-3'); 200 µmol/l deoxynucleoside triphosphates; 1 U of Taq polymerase in 10 × PCR buffer composed of 16.6 mmol/l $(NH_4)_2SO_4$ and 20.0 mmol/l $MgCl_2$, pH 8.8. After initial denaturation for 3 min at 94°C, 39 cycles were performed for 1 min at 94°C (denaturation), for 1 min at 60°C (annealing) and for 1 min at 72°C (extension), followed by a final step for 5 min at 72°C. The *GSTT1* gene has (480 base pair) and *β-globin* gene has (268 base pair), the amplified products were visualized by electrophoresis on ethidium bromide-stained 2% agarose gel (Figure 1).

For deletions of *GSTT1* gene, the no amplified products can be observed, whereas the *β-globin* gene specific fragment confirms the presence of amplifiable DNA in the reaction mixture.

RESULT & DISCUSSION

The study included 40 patients of benign prostatic hyperplasia and 40 controls. The distribution of the genotype of *GSTT1* in control and benign prostatic patients is shown in Table (1).

Detection of *GSTT1* null allele homozygote was carried out by sequence specific amplification using *β-globin* gene as an internal control.

Among patients with benign prostate hyperplasia were 31 (77.5%) had homozygous for the *GSTT1* null allele as compared to the controls (Figure 1).


Figure (1): Show 2% Agarose gel which the PCR amplification of GSTT1 gene and β- globin gene, lane 1: DNA Marker, lane 2 and 3: Normal GSTT1 and β-globin genes of controls, Lane 4,5,6,7,8 and 9 null GSTT1 genes (Absent) in the benign prostatic hyperplasia.

Table (1): Freguency distribution of GSTT1 genotypes and risk of prostate cancer.

Genotype	Control	Patients
GSTT1	40 healthy	40 case
Present	40 (100%)	4 (10%)
Null	0 (0%)	31(77.5%)
Age	59 average	62 average
Smoking	2 (5%)	27(67.5%)

The frequency distribution of *GSTT1* null in benign prostatic hyperplasia was 31 (77.5%) among controls was 0 (0%) as shown in table (1).

The results of our study suggest that polymorphic variations in the glutathione S-transferase (GSTs) are associated with initiation of prostatic cancer susceptibility, that may assumed the presence of carcinogen metabolizing enzymes in human prostate with age may be involved in the regulation of local levels of carcinogens and mutagens and may underlie inter individual differences in cancer susceptibility, these events may agree with Bhurgri *et al.,* (2009) who found that the occurrence of prostate cancer increases many times with increased age as reported in populations of Africa, UK, America, Australia, India and Pakistan.

The risk of genotype *GSTT1* gene null may associated with age that may the smoking status of the

patients in our study play a role in developement of mutation that causing prostate cancer in future because we recorded 67.5% of patients were smokers that may increase the risk of *GSTT1* gene mutation and then intiated prostatic cancer, therefore, prostate tumor and smoking were found to be strongly associated in this study that agreed with many reports in African, Americans and Chinese populations (Leitzmann and Rohrmann, 2012; Islami et al., 2014).

The *GSTT1* gene encode GST enzymes which are involved in the metabolic detoxification of several carcinogens may regarded as a risk factor to initiate cancer like environmental pollution, smoking and age. In addition, in prostate cancer, their involvement in metabolism and intracellular transportation of steroid hormones, provide additional support for these genes to may have a role in prostate carcinogenesis (Listowsky et al., 1988).

In addition the environment and genetics that involved in prostate tumor development may weaken the immune system surveillance and played an important role in the proliferation of tumor in future life of prostatic patients.

GST genes are belong to low penetrence genes and play a role in carcinogenesis of various tumor types, that may agreed with many previous studies revealed that about 20% of the Caucasians lack the GSTT1 genes due to the inherited loss of both alleles that initiate tumors (Mo *et al.,* 2009).

CONCLUSION

It was concluded that smoking, family history of cancer and GSTM1 deletion are risk factors of prostate tumor among Iraqi population.

In addition, we appreciate the stuff members of central researches unit in the college of Vet. Medicine at Uni. Of Basra.

REFERENCES

- Ahmed, J. A.(2014).The role of chitosan in ameliorating the toxic effect of diazinon in laboratory rats immunized by Brucella melitensis. PhD thesis, College of Veterinary Medicine, Uni. Of Baghdad. P 50.

- Bhurgri, Y.; Kayani, N.; Pervez, S.; Ahmed, R.; Tahir, I.; Afif, M.(2009).Incidence and trends of prostate cancer in Karachi South1995–2002. Asian Pacific J Cancer Prev.10(1):45-8.

- Chen, H.; Sandler, D.P.; Taylor, J.A.; Shore, D.L.; Liu, E. Bloomfield, C.D.; Bell, D.A. (1996). Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet, 347: 295-297.

- Garte, S.; Gaspari, L.; Alexandrie, A.K.; Ambrosone, C.; et al. (2001). Metabolic gene polymorphism frequencies in control populations. *Cancer Epidemiol Biomarkers Prev* , 10:1239-1248.

- Gibbs, G.W.; Amsel, J.; Soden, K.(1996).A cohort mortality study of cellulose triacetate fiber workers exposed to methylene chloride. *J Occup Environ Med*; 38 : 693–7.

- Green, M. and Sambrook, J.(2012).Molecular Cloning: A Laboratory Manual. 4th ed. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, New York. 1:82-85.

- Gsur, A.; Haidinger, G.; Hinteregger, S. *et al.*(2001). Polymorphisms of glutathione-Stransferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. *Int J Cancer*; 95: 152–5.

- Islami, F.; Moreira, D.M.; Boffetta, P.; Freedland, S.J. (2014). Asystematic review and meta-analysis of tobacco use and prostate cancer mortality and

incidence in prospective cohort studies. Eur Urol. 66:1054-64.

- Jang, T.L; Yossepowitch, O.; Bianco, F.J.; Scardino, P.T. (2007).Low risk prostate cancer in men under age 65: the case for definitive treatment. *rol Oncol,* 25:510-514.

- Lee, E.; Huang, Y.; Zhao, B.; Seow-Choen, F.; Balakrishnan, A.; Chen, S.H.(1998).Genetic polymorphism of conjugating enzymes and cancer risk. GSTM1, GSTT1, NAT1 and NAT2. *J Toxicol Sci*; 23 (Suppl 2): 140–2.

- Leitzmann, M.F.; Rohrmann, S.(2012). Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol.4:1-11.

- Listowsky, I.; Abramovitz, M.; Homma, H.; Niitsu, Y. (1988). Intracellular binding and transport of hormones and xenobiotics by glutathione-Stransferases. Drug Metab Rev 19: 305-318, 1988.

- Mo, Z.; Gao, Y.; Cao, Y.; et al. (2009). An updating meta analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: A huge review. The Prostate. 69: 662-688.

- Nakazato, H.; Suzuki, K.; Matsui, H. *et al.*(2003). Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in Japanese population. *Anticancer Res*; 23: 2897–902.

- Nebert, D.W.; Vasiliou, V. (2004). Analysis of the glutathione S-transferase (GST) gene family. *Hum Genomics* , 1:460-464.

- Rebbeck, T.R. (1997). Molecular epidemiology of human glutathione Stransferase genotypes *GSTM1* and *GSTT1* in cancer susceptibility. *Cancer Epidemiol Biomarkers Prev*, 6:733-743.

- Siegel, R.; Naishadham, D.; Jemal, A.(2012).Cancer statistics. CA Cancer J Clin ;62:10-29.

- Sreelekha, T.T.; Ramadas, K.; Pandey, M.; Thomas, G.; Nalinakumari, K.R.; Pillai, M.R. (2001).Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. *Oral Oncol*; 37: 593–8.

- Tewari, A.; Johnson, C.; Divine, G.; Crawford, E.D.; Gamito, E.J.; Demers, R.; Menon, M. (2004). Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. *J Urol*, 171:1513-1519.

- Wang, X.; Wang, S.; Lin, Y.W. *et al* .(2012).Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med Oncol, 29:1964-1971.